Contributions
Abstract: P761
Type: Poster
Abstract Category: Therapy - symptomatic - Treatment of specific symptoms
Background: Depressive symptoms are very common in multiple sclerosis (MS). Both depression and MS have been associated with a poor vitamin D status, and cytokine-mediated inflammatory processes play a role in the pathogenesis of both disorders. We hypothesized that vitamin D3 supplementation ameliorates depressive symptoms in MS, and that the immunomodulatory properties of vitamin D explain the effects.
Methods: This study was part of the SOLARIUM trial (NCT01285401), a randomized controlled trial (RCT) in which relapsing remitting (RR) MS patients (n=53) received either high dose vitamin D3 supplementation (14 000 IU/day) or placebo during 48 weeks. Pre- and post-supplementation depression scores were measured in 20 patients in each group, using the subscale Depression of the Hospital Anxiety and Depression Scale (HADS). Furthermore, tumor necrosis factor alpha (TNFα) and interleukin (IL)-10 cytokine secretion by lipopolysaccharide (LPS) stimulated peripheral blood mononuclear cells (PBMC) was measured using Luminex technology, and the proportions of TNFα, interferon-gamma (IFNγ) and IL-10 producing CD8+ T cells were measured using flow cytometry.
Results: After 48 weeks, a significant decrease in HADS depression (HADS-D) scores was observed within the vitamin D3 treated patients (median HADS-D 4.0 to 3.0, p=0.023) and a trend towards a decrease within the placebo group (median HADS-D 3.0 to 2.0, p=0.059), which did not significantly differ between groups (p=0.763). Also, no changes in cytokine secretion, neither by PBMC nor by CD8+
T cells, were found in the vitamin D3 supplemented arm compared to the placebo arm.
Conclusions: In this RCT we found no evidence for amelioration of depressive symptoms in RRMS by vitamin D3 supplementation. Whether vitamin D3 supplementation in actual depression in MS is of benefit, however, needs to be assessed by additional studies.
Disclosure:
LR reports no conflicts of interest;
AM reports no conflicts of interest,
YB reports nog conflicts of interest,
JD reports no conflicts of interest,
JS reports no conflicts of interest,
RH received honoraria for advisory boards and research grants from BIOGEN, SANOFI AVENTIS, NOVARTIS and MERCK.
Abstract: P761
Type: Poster
Abstract Category: Therapy - symptomatic - Treatment of specific symptoms
Background: Depressive symptoms are very common in multiple sclerosis (MS). Both depression and MS have been associated with a poor vitamin D status, and cytokine-mediated inflammatory processes play a role in the pathogenesis of both disorders. We hypothesized that vitamin D3 supplementation ameliorates depressive symptoms in MS, and that the immunomodulatory properties of vitamin D explain the effects.
Methods: This study was part of the SOLARIUM trial (NCT01285401), a randomized controlled trial (RCT) in which relapsing remitting (RR) MS patients (n=53) received either high dose vitamin D3 supplementation (14 000 IU/day) or placebo during 48 weeks. Pre- and post-supplementation depression scores were measured in 20 patients in each group, using the subscale Depression of the Hospital Anxiety and Depression Scale (HADS). Furthermore, tumor necrosis factor alpha (TNFα) and interleukin (IL)-10 cytokine secretion by lipopolysaccharide (LPS) stimulated peripheral blood mononuclear cells (PBMC) was measured using Luminex technology, and the proportions of TNFα, interferon-gamma (IFNγ) and IL-10 producing CD8+ T cells were measured using flow cytometry.
Results: After 48 weeks, a significant decrease in HADS depression (HADS-D) scores was observed within the vitamin D3 treated patients (median HADS-D 4.0 to 3.0, p=0.023) and a trend towards a decrease within the placebo group (median HADS-D 3.0 to 2.0, p=0.059), which did not significantly differ between groups (p=0.763). Also, no changes in cytokine secretion, neither by PBMC nor by CD8+
T cells, were found in the vitamin D3 supplemented arm compared to the placebo arm.
Conclusions: In this RCT we found no evidence for amelioration of depressive symptoms in RRMS by vitamin D3 supplementation. Whether vitamin D3 supplementation in actual depression in MS is of benefit, however, needs to be assessed by additional studies.
Disclosure:
LR reports no conflicts of interest;
AM reports no conflicts of interest,
YB reports nog conflicts of interest,
JD reports no conflicts of interest,
JS reports no conflicts of interest,
RH received honoraria for advisory boards and research grants from BIOGEN, SANOFI AVENTIS, NOVARTIS and MERCK.